A growing understanding of the multiple genetic and environmental pathways that contribute to the development of cancer is leading to the concept of a personalized approach to cancer therapy and prevention. This requires techniques to characterize patient and tumor factors that will drive specific targeted interventions and measure their effectiveness. Biomedical imaging now offers the opportunity to characterize tumor anatomy, physiology, and molecular biology in unprecedented ways. The challenge is to harness this technology to develop quantitative approaches to diagnosis that will support the development and application of targeted treatments and preventive interventions. Since its inception, ACRIN has developed and implemented multicenter clinical trials to establish the effectiveness of imaging in the detection, characterization and monitoring of cancer. Working with its biostatistics center at Brown University, ACRIN has assembled a unique organization of hundreds of clinical imaging specialists, other clinicians, and non-physician researchers at more than a hundred institutions nationally and internationally working collaboratively with the broader cancer research community dedicated to cancer imaging research. Over the next grant cycle, ACRIN proposes 3 major scientific objective related to the theme of personalized cancer care: 1. targeted surveillance of at-risk populations;2.characterization of cancer in order to drive targeted therapy;and 3. development of imaging-based predictive and prognostic biomarkers of response to targeted treatment. Through its continued leadership in the imaging community, ACRIN will play a pivotal role in the advancement of cancer detection and therapy. ACRIN will work to discover ways for imaging to improve cancer care. This includes determining the optimal methods to detect cancer early in order to provide the best opportunity for cure, and establishing techniques to characterize cancer and its response to treatment in order to choose the most appropriate therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA080098-14S3
Application #
8729721
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (O1))
Program Officer
Henderson, Lori A
Project Start
1999-03-06
Project End
2014-12-31
Budget Start
2012-01-01
Budget End
2014-12-31
Support Year
14
Fiscal Year
2013
Total Cost
$65,304
Indirect Cost
$17,512
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Kaufman, Annette R; Dwyer, Laura A; Land, Stephanie R et al. (2018) Smoking-related health beliefs and smoking behavior in the National Lung Screening Trial. Addict Behav 84:27-32
Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184
Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Bittner, Daniel O; Mayrhofer, Thomas; Bamberg, Fabian et al. (2017) Impact of Coronary Calcification on Clinical Management in Patients With Acute Chest Pain. Circ Cardiovasc Imaging 10:
Salavati, Ali; Duan, Fenghai; Snyder, Bradley S et al. (2017) Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 44:1969-1983
Ng, Chaan S; Zhang, Zheng; Lee, Susanna I et al. (2017) CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res 23:3684-3691
Atri, Mostafa; Zhang, Zheng; Dehdashti, Farrokh et al. (2016) Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol 142:413-9
Hylton, Nola M; Gatsonis, Constantine A; Rosen, Mark A et al. (2016) Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279:44-55
Atri, Mostafa; Zhang, Zheng; Marques, Helga et al. (2015) Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. Eur J Radiol Open 2:11-18

Showing the most recent 10 out of 38 publications